Yazar "Aksoy, Sercan" seçeneğine göre listele
Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients(Humana Press Inc, 2012) Elkiran, Emin Tamer; Kaplan, Mehmet Ali; Sevinc, Alper; Aksoy, Sercan; Demirci, Umut; Seker, Mesut; Harputluoglu, HakanMalignant pleural mesothelioma (MPM) is a relatively rare, but aggressive tumor that causes high mortality. The major risk factor involved in the etiology is environmental and occupational exposure to asbestos. The optimal modality of therapy is controversial. The present study retrospectively evaluated the data pertinent to 282 patients who were examined and treated in 11 different medical oncology centers in Turkey. There were 161 males (57.1 %) and 121 females (42.9 %), with a mean age of 56.38 +/- A 12.07 years. Surgery was used in 74 patients, 21 patients (28.4 %) received only chemotherapy and 28 patients (37.8 %) received chemoradiotherapy after surgery. The median survival in patients who were administered adjuvant therapy after surgery was 24 months, while the median survival in patients who had only surgery was 6 months (p = 0.029). 106 patients were administered pemetrexed-platinum combination and 35 patients were administered gemcitabine-platinum combination as front-line chemotherapy. Median survival, 1- and 2-year survival rates in patients who received platinum analogues and pemetrexed or gemcitabine combinations were found statistically similar (p = 0.15). The median survival for all patients with MPM in our study was 18 months. The main factors influencing the overall survival were stage of the disease (p = 0.020), performance status (p < 0.001), asbestos exposure (p = 0.030) and mesothelioma histological subtypes (p < 0.001). Results of our study suggest that multi-modality treatment regimens consisting of surgery, radiotherapy and chemotherapy prolong overall survival. Survival rates in patients who received combining platinum analogues with pemetrexed or gemcitabine as front-line chemotherapy were found similar.Öğe Nazofarenks kanseri hastalarında nötrofil lenfosit oranının prognoz üzerine etkisi, tek merkez deneyimi(2016) Kertmen, Neyran; Aygun, Sevda; Sahin, Yalin S; Solakoglu, Taha; Ozden, Buket; Keskin, Özge; Solak, Mustafa; Sarıcı, Furkan; Diker, Omer; Tasdemir, Vildan; Aksoy, Sercan; Altundağ, KadriÖz:Amaç: Nötrofil lenfosit oranı (NLO ) immünolojik bir parametredir ve tümör immunite ve rekurrensi gibi inflamatuvar cevapları gösterir. Prognoz ile NLO arasındaki en belirgin ilişki kolorektal ve renal kanserde saptanmıştır. Çalışmamızda NLO`nun nazofarenks kanseri hastalarında hastalıksız sağkalım ve genel sağkalım üzerindeki etkisine bakılmıştır. Gerç ve yöntemler: Bu calışmaya Nisan 1998-Şubat 2013 tarihleri arasında Hacettepe Üniversitesi Kanser Enstitüsü, Medikal Onkoloji Bölümüne başvuran 133 nazorafenks kanseri hastası dahil edildi. Tanı anında lokal ileri nazofarenks kanseri tanısı alan hastalar çalışmaya alındı ve metastatik hastalar çalışmaya dahil edilmedi. Hastalar tedavi olarak öncelikle indüksiyon kemoterapisi takibinde konkomitant kemoradyoterapi tedavisi almıştı. Hematolojik parametreler incelendi ve nötrofil lenfosit oranı hesaplandı. Bulgular: Ortalama NLO 2.78 idi ve çok sayıda varyasyonlar göstermekteydi. NLO <2.1 olan hasta grubu 24.8%, NLO 2.1-2.77 olan 25.6%, NLO 2.77-3.85 olan 24.8% ve >3.86 24.8% oranındaydı.Hastaların hastalıksız sağkalım ve genel sağkalım verileri hesaplandı. NLO değerleri ile hastalıksız sağkalım ve genel sağkalım arasında fark saptanmadı (p:0.86 ve p:0.54). Sonuç: Literatürde NLO sadece bağımsız bir prognostik faktör değil aynı zamanda kemoradyoterapi cevabını belirleyen bir prediktif faktördür. Yüksek NLO değerlerinin kötü prognozu, yüksek tümör yükünü ve yüksek malignite gradesini gösterdiğine dair yayınlar mevcuttur. Bunun tersi olarak, çalışmamıza göre nazofarenks kanseri takibinde NLO bir prognostik faktör değildir ve hastalıksız sağkalım ve genel sağkalımın belirlenmesinde etkin değildir.Öğe Outcome of 561 non-metastatic triple negative breast cancer patients: Multi-center experience from Turkey(Imprimatur Publications, 2014) Budakoglu, Burcin; Altundag, Kadri; Aksoy, Sercan; Kaplan, Muhammed A.; Ozdemir, Nuriye Y.; Berk, Veli; Ozkan, MetinPurpose: Triple-negative breast cancers account for 15% of breast carcinomas and, when present as early-stage disease, they are associated with higher rates of recurrence and early distant metastasis risk when compared to hormone receptor positive and human epidermal growth factor receptor (HER-2) positive breast cancers. In this study we aimed to explore the basic clinicopathological characteristics, prognostic factors and recurrence patterns of non-metastatic triple negative breast cancer patients. Methods: In this study 561 non-metastatic triple-negative breast cancer female patients admitted to 8 different cancer centers in Turkey between 2000 and 2010 were retrospectively evaluated through their medical records, to identify the basic clinico-pathological characteristics, prognostic factors and recurrence patterns. Results: The ratio of triple-negative breast cancer was 12%. The median age of patients was 48 years, of whom 311 (55.4%) were premenopausal. The majority had early-stage breast cancer at the time of diagnosis (16.8% stage I, 48.1% stage II, 35.1 % stage III) and the most commonly identified variant was invasive ductal carcinoma (84.1%). Grade II and III tumors were 27.1 and 48.5%, respectively. Adjuvant chemotherapy was administered to 90.5% of women and adjuvant radiotherapy to 41.2%. Median patient follow up was 28 months (range 3-290). During the follow up period 134 (23.8%) patients developed metastatic disease. In most of these cases, metastatic sites were bone, soft tissue, and lung. Factors affecting disease free survival (DFS) and overall survival (OS) were age (both p<0.001), lymph node involvement (both p<0.001), lymphovascular invasion (LVI) (p<0.001 and p=0.004, respectively), tumor stage (both p<0.001), adjuvant administration of anthracycline-based chemotherapy (both <0.001) and type of surgery (not significant for DFS but p=0.05 for OS). Three-year DFS and OS were 72.0 and 93.0%, respectively. Conclusion: Age, lymph node involvement, LVI, stage, and adjuvant chemotherapy were determined as prognostic factors for DFS and OS. The most common recurrence sites were bone, soft tissue and the lung. Further prospective randomised trials are needed to confirm the prognostic and predictive factors identified in this study.Öğe Results of Adjuvant FOLFOX Regimens in Stage III Colorectal Cancer Patients: Retrospective Analysis of 667 Patients(Karger, 2013) Uncu, Dogan; Aksoy, Sercan; Cetin, Bulent; Yetisyigit, Tarkan; Ozdemir, Nuriye; Berk, Veli; Dane, FaysalObjective: The aim of this study was to assess the use of 5-fluorouracil (5-FU), leucovorin and oxaliplatin (FOLFOX) regimens in clinical practice according to their efficacy and toxicity. Methods: Patients who received oxaliplatin-containing regimens after curative resection for colorectal carcinoma from 10 different oncology centers between May 2004 and December 2009 were included in the study. All patients were treated with FOLFOX regimens. Patients with rectal carcinoma were also treated with chemoradiotherapy with 5-FU after 2 cycles of a FOLFOX regimen. Results: The median age of the patients was 56 years (range 17-78). Of the total 667 patients, 326 were given FOLFOX-4, 232 were given modified FOLFOX-4 and 109 were given FOLFOX-6. The distribution according to disease stage was 33 patients with stage IIIA colorectal cancer, 382 patients with stage IIIB and 252 patients with stage IIIC. The most common adverse events were neutropenia (54%), nausea (36.9%), neuropathy (38.2%) and anemia (33.1%) for all grades. The median follow-up time was 23 months (range 1-79). Three-year disease-free survival and overall survival were 65 and 85.7%, respectively. Conclusion: The different oxaliplatin-containing 5-FU-based adjuvant chemotherapy regimens in patients with stage III colorectal cancer seemed to be at least equal in terms of efficacy regardless of the method of 5-FU administration or oxaliplatin dose. Copyright (C) 2012 S. Karger AG, Basel
